Enrollment completed in first palonosetron Phase III

MGI Pharma (MOGN) partner Helsinn (Lugano, Switzerland) completed enrollment in the first Phase III trial comparing Helsinn's intravenous palonosetron, a 5-HT3 antagonist, to marketed 5-HT3 antagonist...